Clinical Trials Browser

Terminated × Ovarian Neoplasms × Melphalan × Clear all

NCT03691376 2024-09-19

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Terminated

4 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00003926 2017-11-29

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Phase 1 Terminated

13 enrolled

CNSGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcoma

Ovarian Germ Cell Cancer, Astrocytoma, Brain Neoplasms, Chordoma, Ependymoma, Glioma, Kidney Neoplasms, Liver Neoplasms, Medulloblastoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Neuroectodermal Tumors, Hepatoblastoma, Desmoplastic Small Round Cell Tumor

NCT00583622 2013-05-21

Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

Phase 2 Terminated

13 enrolled 5 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00523809 2013-01-28

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Phase 2 Terminated

5 enrolled 4 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms